论文部分内容阅读
目的:探讨儿童支气管肺炎采用不同种类头孢类药物治疗效果及成本。方法:本次共选择160例支气管肺炎患儿作研究对象,均为我院儿科2013年1月至2014年1月收治,采用数字表抽取法随机分组,就头孢噻肟钠(安万特)(A组,n=40)、头孢呋辛(n=40)、头孢哌酮舒巴坦钠(C组,n=40)、头孢他啶(D组,n=40)治疗效果、成本进行比较。结果:A组总有效率为92.5%,B组总有效率为90%,C组总有效率为87.5%;D组总有效率为85%,A组即头孢噻肟钠(安万特)效果最为显著,但各组无明显差异(P>0.05)。成本方面,C组即头孢哌酮舒巴坦钠最低,后为A组、D组、B组,故在药效保证的情况下,头孢哌酮舒巴坦钠可相对减轻经济负担。结论:通过对儿童支气管肺炎患者采用不同种类头孢类药物成本和效果进行分析,临床用药时需对患者具体情况、作用特点、药品价格综合考虑,以选择最为理想的方案,达到有效、安全、经济用药。
Objective: To investigate the effect and cost of different types of cephalosporins in children with bronchopneumonia. Methods: A total of 160 children with bronchopneumonia were selected as the study subjects. All of them were admitted to our pediatric department from January 2013 to January 2014 and were randomly divided into three groups: cefotaxime (Aventis) (Group A, n = 40), cefuroxime (n = 40), cefoperazone sulbactam (group C, n = 40) and ceftazidime (group D, n = 40). Results: The total effective rate was 92.5% in group A, 90% in group B and 87.5% in group C. The total effective rate in group D was 85%. Group A was cefotaxime sodium (Aventis) The effect was the most obvious, but there was no significant difference among the groups (P> 0.05). In terms of cost, cefoperazone and sulbactam sodium was the lowest in group C, followed by group A, group D and group B. Therefore, cefoperazone-sulbactam sodium could relatively reduce the economic burden when the drug efficacy was guaranteed. Conclusion: Through analyzing the cost and effect of using different kinds of cephalosporins in children with bronchopneumonia, the clinical application should be based on the specific conditions, the characteristics of the patients and the price of the drugs, in order to select the most ideal solution to achieve effective, safe and economical Medication.